Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options
BOZEMAN, Mont., Oct. 7, 2025 /PRNewswire/ — Golden Helix, Inc. announced that it was awarded the NIH SBIR Grant 2R44HG013456-02 “Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options.”
Pharmacogenomics is expanding clinicians’ ability to deliver personalized medicine, enabling drug selection, dosage, efficacy, and safety to be tailored to each patient’s unique biological needs. With support from the NIH SBIR Grant, Golden Helix will enhance its pharmacogenetic analytics as an integrated component of NGS-based genetic testing, driving more precise and scalable solutions for clinical practice.
Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R44HG013456. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The PI of this grant, Dr. Andreas Scherer, President and CEO of Golden Helix, expressed his appreciation, “We are extremely grateful for the long-standing support of the NIH for our research, spanning from CNV analysis to clinical interpretation, and now to pharmacogenomics. This latest grant is a testament to our commitment to bringing advanced research topics to the marketplace. With this generous funding, we will build a world-class enterprise platform for pharmacogenomics. We are also deeply appreciative of the support from leading organizations in the NGS industry, whose letters of support underscore the strategic importance of this research project.”
With support from the NIH SBIR Grant, Golden Helix will continue advancing its precision medicine software, equipping clinicians with tools to identify actionable insights that inform individualized treatment decisions. As the demand for PGx solutions grows, the company remains committed to delivering high-quality, clinically relevant technologies designed to support scalable and cost-effective implementation across healthcare settings.
About Golden Helix
Golden Helix has delivered trusted bioinformatics solutions for over 25 years to hospitals, testing labs, research institutions, and national genome programs around the world. With powerful tools for tertiary analysis and genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and accelerate discoveries in rare diseases and oncology. Since 2017, the company has received a total of $7 million in funding from the NIH.
Hayley Karol
Technical Marketing Specialist
Golden Helix, Inc
(406) 414- 9973
Karol@goldenhelix.com
SOURCE Golden Helix Inc
Regional program delivers double-digit sales growth, improved service performance, and expanded diagnostic access across Latin…
Four new products available now to put full diagnostics in the palm of technician's handsSPARKS,…
Global leaders, entrepreneurs and innovators will converge across the Tampa Medical & Research District and…
IPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ -- New England Biolabs (NEB ®) will present several…
PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…
NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning…